Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 17/20 | 1.00 |
| ▸ | KCNQ2 | O43526 | 17/20 | 1.00 |
| ▸ | KCNQ4 | P56696 | 1/20 | 1.00 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 1.00 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3676017 | 0.75 | KCNQ2 (0.64) | KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL21089645 | 0.74 | KCNQ2 (0.59) | KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL21132316 | 0.73 | KCNQ2 (0.57) | KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL12955241 | 0.71 | KCNQ2 (0.59) | KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL13991580 | 0.71 | KCNQ2 (0.66) | KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL3672298 | 0.71 | KCNQ2 (0.58) | KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL21089527 | 0.70 | KCNQ2 (0.53) | KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL320941 | 0.70 | KCNQ3 (0.52) | KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL322079 | 0.67 | KCNQ3 (0.50) | KCNQ3KCNQ2KCNQ4KCNQ5KDM4E | |
| SCHEMBL3095470 | 0.67 | KCNQ2 (0.72) | KCNQ3KCNQ2KCNQ4KCNQ5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883812-B2 | Piperidinyl pyrimidine amides as Kv7 potassium channel openers | PFIZER INC. (US) | 2014-11-11 | — | — | US | claimed |
| US-20130150391-A1 | Piperidinyl Pyrimidine Amides As KV7 Potassium Channel Openers | PFIZER INC. (US) | 2013-06-13 | — | — | US | claimed |
| EP-2590961-A1 | PIPERIDINYL PYRIMIDINE AMIDES AS KV7 POTASSIUM CHANNEL OPENERS | Pfizer Inc (US) | 2013-05-15 | — | — | EP | claimed |
| WO-2012004698-A1 | PIPERIDINYL PYRIMIDINE AMIDES AS KV7 POTASSIUM CHANNEL OPENERS | PFIZER INC. (US) | 2012-01-12 | — | — | WO | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| US-20240226054-A9 | AGENTS AND METHODS FOR PREVENTING AND TREATING SKELETAL MUSCLE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240131000-A1 | AGENTS AND METHODS FOR PREVENTING AND TREATING SKELETAL MUSCLE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-8883812-B2 | Piperidinyl pyrimidine amides as Kv7 potassium channel openers | PFIZER INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883812-B2 | Piperidinyl pyrimidine amides as Kv7 potassium channel openers | PFIZER INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130150391-A1 | Piperidinyl Pyrimidine Amides As KV7 Potassium Channel Openers | PFIZER INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150391-A1 | Piperidinyl Pyrimidine Amides As KV7 Potassium Channel Openers | PFIZER INC. (US) | 2013-06-13 | — | — | US | disclosed |
| EP-2590961-A1 | PIPERIDINYL PYRIMIDINE AMIDES AS KV7 POTASSIUM CHANNEL OPENERS | Pfizer Inc (US) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004698-A1 | PIPERIDINYL PYRIMIDINE AMIDES AS KV7 POTASSIUM CHANNEL OPENERS | PFIZER INC. (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150391-A1 | Piperidinyl Pyrimidine Amides As KV7 Potassium Channel Openers | KCNA7, KCNK17, KCNQ5 | KCNQ3 6/4885KCNQ2 4/4885KCNQ4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.